Infectious disease and vaccines: clinical-trial pipeline
48,117 infectious disease and vaccines trials are in ClinicalTrials.gov and the EU CTIS portal; 6,728 are not yet finished and 627 of those are in phase 2/3 or 3. Source: Arcadium Data, data as of .
Open trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 4,145 |
| Phase 2 | 679 |
| Phase 4 | 566 |
| Phase 3 | 530 |
| Phase 1 | 422 |
| Phase 1/2 | 207 |
| Phase 2/3 | 97 |
| Early phase 1 | 82 |
Sponsors with the most open trials
Recently changed open trials
| Registry id | Title | Sponsor | Phase | Status | Countries |
|---|---|---|---|---|---|
| NCT05169229 | Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. | University Hospital, Linkoeping | Phase 2 | Not yet recruiting | Denmark, Sweden |
| NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | UMC Utrecht | Phase 3 | Active, not recruiting | Australia, Belgium, Canada, Switzerland +25 |
| 2023-509071-16-00 | Renal Outcomes in the early use of vasopressin in the treatment of septic shock | Azienda Unita Sanitaria Locale Di Bologna | Phase 4 | Recruiting | Italy |
| NCT05705349 | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | Merck Sharp & Dohme LLC | Phase 3 | Active, not recruiting | Argentina, Canada, Switzerland, Chile +16 |
| NCT05389319 | A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults | University Hospital Tuebingen | Phase 1 | Active, not recruiting | Germany |
| NCT06290557 | First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133 | University Hospital Tuebingen | Phase 1 | Recruiting | Germany |
| NCT06668727 | Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study) | Aarhus University Hospital | Phase 1 | Recruiting | Germany, Denmark |
| NCT06184659 | Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis | Scandinavian Critical Care Trials Group | Phase 4 | Not yet recruiting | Denmark, Sweden |
| NCT05444699 | Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age | University of Oulu | Phase 4 | Recruiting | Finland |
| NCT05294796 | Efficacy and Safety of Antimicrobial Durations Treatment of Infections Associated With Osteosynthesis Material | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 3 | Recruiting | Spain |
| NCT04665037 | Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-12… | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Belgium, Greece, Israel, South Korea +6 |
| 2022-501707-27-01 | European Clinical Research Alliance on Infectious Diseases – primary care adaptive platform trial for pandemi… | University Medical Center Utrecht | Phase 2/3 | Active, not recruiting | Belgium, Germany, Spain, France +2 |
| NCT05319353 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for th… | Takeda | Phase 3 | Recruiting | Australia, Belgium, Brazil, China +7 |
| 2023-504288-18-00 | A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 t… | Zhejiang Yaoyuan Biotechnology Co. Ltd. | Phase 1 | Not yet recruiting | Bulgaria, Romania |
| NCT05394298 | Short vs Long of Usual Treatment for Non Complicated Enterococcal Bacteremia | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 4 | Active, not recruiting | Spain |
| 2024-513168-24-00 | A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1… | University College Dublin | Phase 2 | Recruiting | Denmark, Ireland, Italy |
| 2024-512681-34-00 | Pharmacokinetics of a novel extended infusion regimen of fosfomycin | Medical University Of Vienna | Phase 1 | Recruiting | Austria |
| NCT04936685 | Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administ… | Sanofi Pasteur, a Sanofi Company | Phase 3 | Active, not recruiting | Germany, Spain, Finland, Hungary |
| 2023-509777-23-00 | E. coli Urinary Tract Infection Study | Phagenix | Phase 1 | Not yet recruiting | France |
| NCT04232917 | Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections. | Labo'Life | Phase 4 | Recruiting | Belgium, Romania |
All areas: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Infectious disease and vaccines clinical trials: 6,728 open, 627 in phase 3", https://arcadiumdata.io/clinical-trials/area/infectious-disease/, data as of 2026-10-25.